| |
 |
DNA encoding interleukin-B30 |
| RE39015 |
DNA encoding interleukin-B30
|
|
| Patent Drawings: | |
| Inventor: |
Bazan |
| Date Issued: |
March 14, 2006 |
| Application: |
09/935,366 |
| Filed: |
August 22, 2001 |
| Inventors: |
Bazan; J. Fernando (Palo Alto, CA)
|
| Assignee: |
Schering Corporation (Kenilworth, NJ) |
| Primary Examiner: |
Mertz; Prema |
| Assistant Examiner: |
|
| Attorney Or Agent: |
Hill; Laurie L.Ching; Edwin P. |
| U.S. Class: |
435/252.3; 435/254.11; 435/320.1; 435/325; 435/471; 435/69.52; 435/71.1; 435/71.2; 530/351; 536/23.1; 536/23.5 |
| Field Of Search: |
435/69.52; 435/70.1; 435/71.1; 435/71.2; 435/725; 435/421; 435/320.1; 435/252.3; 435/254.11; 536/23.1; 536/23.5; 536/24.3; 536/24.31; 530/350; 530/357 |
| International Class: |
C12N 15/24; C07K 14/54; C12N 15/63; C12N 5/10 |
| U.S Patent Documents: |
|
| Foreign Patent Documents: |
|
| Other References: |
Voet et al. Biochemistry. 1990. John Wiley & Sons, Inc. pp. 126-128 and 228-234. cited by examiner.
Doerks et al. Protein annotation: detective work for function prediction. Trends in Genetics. Jun. 1998, vol. 14, No. 6, pp. 248-250. cited by exam- iner.
Brenner et al. Errors in Genome Annotation. Trends in Genetics 1999, 15:132-133. cited by examiner.
Bork et al. Go Hunting in sequence databases but watch out for the traps. Trends in Genetics 1996, 12:425-427. cited by examiner.
Bork et al., Current Opinion in Structural Biology (1998) 8:331-332. cited by other.
Ngo et al., The Protein Folding Problem and Tertiary Structure Prediction (1994) pp. 492-495. cited by other.
Schafer et al., Gene (1993) 136:295-300. cited by other.
Skolnick et al., Tibtech (2000) 18:34-39. cited by other.
Wells, Aditivity of Mutational Effects in Proteins, Biochemistry (1990) 26(37):8509-8517. cited by other.
F.R. Blattner, et al., GenPept, Accession No. 2506659, Nov. 1, 1997. Definition: "Hypothetical 55.1 KD Protein in OGT-DBPA Intergenic Region." cited by examiner.
T.D. Gaffney, et al., GenPept, Accession No. 1172467, Nov. 1, 1995. Definition: "CDP-Diacylglycerol--Glycerol-3-Phosphate 3-Phosphatidyltransferase (Phosphatidylglycerophosphate Synthase) (PGP Synthase)." cited by examiner.
Toshio Hirano, The Cytokine Handbook, Angus W. Thompson, Editor, 2nd Ed., Ch. 8:145-168, Academic Press, San Diego, 1994. "Interleukin-6". cited by examiner.
L. Hillier, et al., GenBank, Accession No. AA418955, Oct. 16, 1997. Definition: "zw01c10.r1 Soars NhHMPu S1 Homo sapiens cDNA clone 768018 5'." cited by examiner.
Y. Ito, GenBank, Accession No. AB004061, Jun. 2, 1997. Definition: "domestic pig mRNA for STAT2, complete cds." cited by examiner.
Shigekazu Nagata, The Cytokine Handbook, Angus W. Thompson, Editor, 2nd Ed., Ch. 20:371-385-168, Academic Press, San Diego, 1994. "Granulocyte Colony Stimulation Factor and its Receptor". cited by examiner.
W. Northemann, et al., GenPept, Accession No. 111880, Jun. 18, 1993. Definition: "interleukin-6-precursor--rat." cited by examiner.
W. Northemann, et al., GenPept, Accession No. 124350, Jul. 15, 1998. Definition: "Interleukin-6 Precursor (IL-6)". cited by examiner.
J. Takeda, GenBank, Accession No. C06368, Oct. 11, 1996. Definition: "similar to none". cited by examiner.
M. Tsuchiya, et al., GenPept, Accession No. 117565, Jul. 15, 1998. Definition: "Granulocyte Colony-Stimulating Factor Precursor (G-CSF)." cited by examiner.
M. Tsuchiya, et al., GenPept, Accession No. 90543, Jun. 7, 1996. Definition: "granulocyte colony-stimulating factor precursor--mouse." cit- ed by examiner.
J. Van Snick, et al., GenPept, Accession No. 124348, Jul. 15, 1998. Definition: Interleukin-6 Precursor (IL-6) (Interleukin HP-1) (B-Cell Hybridoma Growth Factor). cited by examiner.
J. Van Snick, et al., GenPept, Accession No. 69691, Jun. 7, 1996. Definition "interleukin-6 precursor--mouse." cited by examiner. |
|
| Abstract: |
Purified genes encoding cytokines from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using the reagents and diagnostic kits are also provided. |
| Claim: |
What is claimed is:
1. An isolated or recombinant polynucleotide encoding an antigenic polypeptide comprising: a) at least 17 contiguous amino acids from a mature coding portion of SEQ ID NO: 2,b) at least 17 contiguous amino acids from a mature coding portion of SEQ ID NO: 4; or c) at least 17 contiguous amino acids from a mature coding portion of SEQ ID NO: 5.
2. The polynucleotide of claim 1, encoding a mature polypeptide of: a) SEQ ID NO: 2; b) SEQ ID NO: 4; or c) SEQ ID NO: 5.
3. The polynucleotide of claim 1, which encodes amino residues 155-164 of SEQ ID NO: 2 and hybridizes under stringent wash conditions of at least 65.degree. C., less than about 150 mM salt to the complement of: a) the open reading frame of SEQID NO: 1; or b) the open reading frame of SEQ ID NO: 3.
4. The polynucleotide of claim 3, comprising: a) at least 67 contiguous nucleotides of a coding portion of SEQ ID NO: 1, wherein said contiguous nucleotides are from nucleotides 466-555 of SEQ ID NO: 1; or b) at least 67 contiguous nucleotidesof a coding portion of SEQ ID NO: 3, wherein said contiguous nucleotides are from nucleotides 580-670 of SEQ ID NO: 3.
5. A recombinant or expression vector comprising said polynucleotide of claim 1.
6. An isolated host cell comprising said expression vector of claim 5.
7. A method of making an antigenic polypeptide comprising expressing said recombinant polynucleotide of claim 1 and isolating said polypeptide, thereby making said antigenic polypeptide.
8. Said polynucleotide of claim 1, wherein said contiguous amino acids number 20.
9. Said polynucleotide of claim 1, wherein said contiguous amino acids number 30.
10. Said polynucleotide of claim 1, wherein said contiguous amino acids number 35.
11. Said polynucleotide of claim 1, wherein said contiguous amino acids number 40.
12. Said polynucleotide of claim 2, that is a variant due to the degeneracy of the genetic code.
13. The polynucleotide of claim 8, wherein said wash conditions are a) at least 70.degree. C.; b) less than about 100 mM salt; or c) both a) and b).
14. The polynucleotide of claim 3, wherein said wash conditions a) are at least 50% formamide; b) are less than about 100 mM salt; or c) are both a) and b).
15. The polynucleotide of claim 1, that: a) encodes the mature polypeptide of SEQ ID NO:2,4, or 5; or b) comprises the mature coding portion of SEQ ID NO: 1 or 3.
16. The polynucleotide of claim 2, wherein said polynucleotide: a) encodes a polypeptide with a natural sequence of the mature coding portion of SEQ ID NO: 2 or 4; b) is isolated from nature; c) encodes a polypeptide comprising five or fewerconservative substitutions from a natural sequence of SEQ ID NO: 2 or 4; d) encodes a polypeptide comprising five or fewer conservative substitutions from a natural sequence of SEQ ID NO: 4.
17. The polynucleotide of claim 8, which: a) is attached to a solid substrate; b) is detectably labeled; c) is in a sterile composition; d) encodes an antigenic polypeptide having at least 12 amino acid residues; or e) is syntheticallyproduced.
18. An isolated or recombinant polynucleotide encoding a polypeptide of: a) SEQ ID NO:2; b) SEQ ID NO:4; or c) SEQ ID NO:5.
19. A recombinant or expression vector comprising said polynucleotide of claim 18.
20. An isolated host cell comprising said expression vector of claim 19.
21. A method of making a polypeptide comprising expressing said recombinant polynucleotide of claim 18 and isolating said polypeptide, thereby making said polypeptide.
22. The polynucleotide of claim 18, that is a variant due to the degeneracy of the genetic code.
23. An isolated or recombinant polynucleotide that: a) encodes the mature polypeptide of SEQ ID NO: 2, 4, or 5; or b) comprises the mature coding portion of SEQ ID NO: 1 or 3.
24. The polynucleotide of claim 18, wherein said polynucleotide is isolated from a human or a mouse.
25. The polynucleotide of claim 18, which: a) is attached to a solid substrate; b) is detectably labeled; c) is in sterile composition; or d) is synthetically produced.
26. A recombinant or expression vector comprising said polynucleotide of claim 23.
27. An isolated host cell comprising said expression vector of claim 26.
28. A method of making a polypeptide comprising expressing said recombinant polynucleotide of claim 23 and isolating said polypeptide, thereby making said polypeptide.
29. The polynucleotide of claim 23, that is a variant due to the degeneracy of the genetic code.
30. The polynucleotide of claim 23, wherein said polynucleotide is isolated from a human or a mouse.
31. The polynucleotide of claim 23, which: a) is attached to a solid substrate; b) is detectably labeled; c) is in sterile composition; or d) is synthetically produced. |
| Description: |
FIELD OFTHE INVENTION
The present invention pertains the compositions related to proteins which function in controlling biology and physiology of mammalian cells, e.g., cells of a mammalian immune system. In particular, it provides purified genes, proteins,antibodies, and related reagents useful, e.g., to regulate activation, development, differentiation, and function of various cell types, including hematopoietic cells.
BACKGROUND OF THE INVENTION
Recombinant DNA technology refers generally to the technique of integrating genetic information from a donor source into vectors for subsequent processing, such as through introduction into a host, whereby the transferred genetic information iscopied and/or expressed in the new environment. Commonly, the genetic information exists in the form of complementary DNA (cDNA) derived from messenger RNA (mRNA) coding for a desired protein product. The carrier is frequently a plasmid having thecapacity to incorporate cDNA for later replication in a host and, in some cases, actually to control expression of the cDNA and thereby direct synthesis of the encoded product in the host.
For some time, it has been known that the mammalian immune response is based on a series of complex cellular interactions, called the "immune network". Recent research has provided new insights into the inner workings of this network. While itremains clear that much of the response does, in fact, revolve around the network-like interactions of lymphocytes, macrophages, granulocytes, and other cells, immunologists now generally hold the opinion that soluble proteins, known as lymphokines,cytokines, or monokines, play a critical role in controlling these cellular interactions. Thus, there is considerable interest in the isolation, characterization, and mechanisms of action of cell modulatory factors, an understanding of which will leadto significant advancements in the diagnosis and therapy of numerous medical abnormalities, e.g., immune system disorders. Some of these factors are hematopoietic growth factors, e.g., granulocyte colony stimulatory factor (G-CSF). See, e.g., Thomson(1994; ed.) The Cytokine Handbook (2d ed.) Academic Press, San Diego; Metcalf and Nicola (1995) The Hematopoietic Colony Stimulatory Factors Cambridge University Press; and Aggarwal and Gutterman (1991) Human Cytokines Blackwell Pub.
Lymphokines apparently mediate cellular activities in a variety of ways. They have been shown to support the proliferation, growth, and differentiation of pluripotential hematopoietic stem cells into vast numbers of progenitors comprisingdiverse cellular lineages making up a complex immune system. Proper and balanced interactions between the cellular components are necessary for a healthy immune response. The different cellular lineages often respond in a different manner whenlymphokines are administered in conjunction with other agents.
Cell lineages especially important to the immune response include two classes of lymphocytes: B-cells, which can produce and secrete immunoglobulins (proteins with the capability of recognizing and binding to foreign matter to effect itsremoval), and T-cells of various subsets that secrete lymphokines and induce or suppress the B-cells and various other cells (including other T-cells) making up the immune network. These lymphocytes interact with many other cell types.
Another important cell lineage is the mast cell (which has not been positively identified in all mammalian species), which is a granule-containing connective tissue cell located proximal to capillaries throughout the body. These cells are foundin especially high concentrations in the lungs, skin, and gastrointestinal and genitourinary tracts. Mast cells play a central role in allergy-related disorders, particularly anaphylaxis as follows: when selected antigens crosslink one class ofimmunoglobulins bound to receptors on the mast cell surface, the mast cell degranulates and releases mediators, e.g., histamine, serotonin, heparin, and prostaglandins, which cause allergic reactions, e.g., anaphylaxis.
Research to better understand and treat various immune disorders has been hampered by the general inability to maintain cells of the immune system in vitro. Immunologists have discovered that culturing these cells can be accomplished through theuse of T-cell and other cell supernatants, which contain various growth factors, including many of the lymphokines.
From the foregoing, it is evident that the discovery and development of new lymphokines, e.g., related to G-CSF and/or IL-6, could contribute to new therapies for a wide range of degenerative or abnormal conditions which directly or indirectlyinvolve the immune system and/or hematopoietic cells. In particular, the discovery and development of lymphokines which enhance or potentiate the beneficial activities of known lymphokines would be highly advantageous. The present invention providesnew interleukin compositions and related compounds, and methods for their use.
SUMMARY OF THE INVENTION
The present invention is directed to mammalian, e.g., rodent, canine, feline, primate, interleukin-B30 (IL-B30) and its biological activities. It includes nucleic acids coding for polypeptides themselves and methods for their production and use. The nucleic acids of the invention are characterized, in part, by their homology to cloned complementary DNA (cDNA) sequences enclosed herein, and/or by functional assays for growth factor- or cytokine-like activities, e.g., G-CSF (see Nagata (1994) inThomson The Cytokine Handbook 2d ed., Academic Press, San Diego) and/or IL-6 (see Hirano (1994) in Thomson The Cytokine Handbook 2d ed., Academic Press, San Diego), applied to the polypeptides, which are typically encoded by these nucleic acids. Methodsfor modulating or intervening in the control of a growth factor dependent physiology or an immune response are provided.
The present invention is based, in part, upon the discovery of a new cytokine sequence exhibiting significant sequence and structural similarity to G-CSF and IL-6. In particular, it provides primate, e.g., human, gene encoding a protein whosemature size is about 168 amino acids, and pig and murine, e.g., mouse, sequences. Functional equivalents exhibiting significant sequence homology will be available from other mammalian, e.g., cow, horse, and rat, and non-mammalian species.
In various protein embodiments, the invention provides: a substantially pure or recombinant IL-B30 protein or peptide exhibiting at least about 85% sequence identity over a length of at least about 12 amino acids to SEQ ID NO: 2; a naturalsequence IL-B30 of SEQ ID NO: 2; and a fusion protein comprising IL-B30 sequence. In certain embodiments, the homology is at least about 90% identity and the portion is at least about 9 amino acids; the homology is at least about 80% identity and theportion is at least about 17 amino acids; or the homology is at least about 70% identity and the portion is at least about 25 amino acids. In other embodiments, the IL-B30: comprises a mature sequence of Table 1; or exhibits a post-translationalmodification pattern distinct from natural IL-B30; or the protein or peptide: is from a warm blooded animal selected from a mammal, including a primate; comprises at least one polypeptide segment of SEQ ID NO: 2; exhibits a plurality of portionsexhibiting the identity; is a natural allelic variant of IL-B30; has a length at least about 30 amino acids; exhibits at least two non-overlapping epitopes which are specific for a mammalian IL-B30; exhibits a sequence identity at least about 90% over alength of at least about 20 amino acids to mammalian IL-B30; is glycosylated; has a molecular weight of at least 10 kD with natural glycosylation; is a synthetic polypeptide; is attached to a solid substrate; is conjugated to another chemical moiety; isa 5-fold or less substitution from natural sequence; or is a deletion or insertion variant from a natural sequence. Preferred embodiments include a composition comprising: a sterile IL-B30 protein or peptide; or the IL-B30 protein or peptide and acarrier, wherein the carrier is: an aqueous compound, including water, saline, and/or buffer; and/or formulated for oral, rectal, nasal, topical, or parenteral administration. In fusion protein embodiments, the protein can have: mature protein sequenceof Table 1; a detection or purification tag, including a FLAG, His6, or Ig sequence; and/or sequence of another cytokine or chemokine.
Kit embodiments include those with an IL-B30 protein or polypeptide, and: a compartment comprising the protein or polypeptide; and/or instructions for use or disposal of reagents in the kit.
In binding compound embodiments, the compound may have an antigen binding site from an antibody, which specifically binds to a natural IL-B30 protein, wherein: the IL-B30 is a mammalian protein; the binding compound is an Fv, Fab, or Fab2fragment; the binding compound is conjugated to another chemical moiety; or the antibody: is raised against a peptide sequence of a mature polypeptide of Table 1; is raised against a mature IL-B30; is raised to a purified rodent IL-B30; isimmunoselected; is a polyclonal antibody; binds to a denatured IL-B30; exhibits a Kd of at least 30 .mu.M; is attached to a solid substrate, including a bead or plastic membrane; is in a sterile composition; or is detectably labeled, including aradioactive or fluorescent label. Kits containing binding compounds include those with: a compartment comprising the binding compound; and/or instructions for use or disposal of reagents in the kit. Often the kit is capable of making a qualitative orquantitative analysis. Preferred compositions will comprise: a sterile binding compound; or the binding compound and a carrier, wherein the carrier is: an aqueous compound, including water, saline, and/or buffer; and/or formulated for oral, rectal,nasal, topical, or parenteral administration.
Nucleic acid embodiments include an isolation or recombinant nucleic acid encoding an IL-B30 protein or peptide or fusion protein, wherein: the IL-B30 is from a mammal; and/or the nucleic acid: encodes an antigenic peptide sequence of Table 1;encodes a plurality of antigenic peptide sequences of Table 1; exhibits at least about 80% identity to a natural cDNA encoding the segment; is an expression vector; further comprises an origin of replication; is from a natural source; comprises adetectable label; comprises synthetic nucleotide sequence; is less than 6 kb, preferably less than 3 kb; is from a mammal, including a primate; comprises a natural full length coding sequence; is a hybridization probe for a gene encoding the IL-B30; oris a PCR primer, PCR product, or mutagenesis primer. The invention also provides a cell, tissue, or organ comprising such a recombinant nucleic acid, and preferably the cell will be: a prokaryotic cell; a eukaryotic cell; a bacterial cell; a yeast cell;an insect cell; a mammalian cell; a mouse cell; a primate cell; or a human cell.
Kit embodiments include those with such nucleic acids, and: a compartment comprising the nucleic acid; a compartment further comprising the IL-B30 protein or polypeptide; and/or instructions for use or disposal of reagents in the kit. Typically,the kit is capable of making a qualitative or quantitative analysis.
In certain embodiments, the nucleic acid: hybridizes under wash conditions of 30.degree. C. and less than 2M salt, or of 45.degree. C. and/or 500 mM salt, or 55.degree. C. and/or 150 mM salt, to SEQ ID NO: 1; or exhibits at least about 85%identity and/or the stretch is at least about 30 nucleotides, or exhibits at least 90% identity and/or the stretch is at least 55 nucleotides, or exhibits at least 95% and/or the stretch is at least 75 nucleotides, to a primate IL-B30.
The invention embraces a method of modulating physiology or development of a cell or tissue culture cells comprising contacting the cell with an agonist or antagonist of a mammalian IL-B30. The method may be where: the contacting is incombination with an agonist or antagonist of G-CSF and/or IL-6; or the contacting is with an antagonist, including a binding composition comprising an antibody binding site which specifically binds an IL-B30.
DETAILED DESCRIPTION OF THE PREFERREDEMBODIMENTS
All references cited herein are incorporated herein by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
OUTLINE
I. General
II. Purified IL-B30
A. physical properties
B. biological properties
III. Physical Variants
A. sequence variants, fragments
B. post-translational variants 1. glycosylation 2. others IV. Functional Variants
A. analogs, fragments 1. agonists 2. antagonists
B. mimetics 1. protein 2. chemicals
C. species variants
V. Antibodies
A. polyclonal
B. monoclonal
C. fragments, binding compositions
VI. Nucleic Acids
A. natural isolates; methods
B. synthetic genes
C. methods to isolate
VII. Making IL-B30, mimetics
A. recombinant methods
B. synthetic methods
C. natural purification
VIII. Uses
A. diagnostic
B. therapeutic
IX. Kits
A. nucleic acid reagents
B. protein reagents
C. antibody reagents
X. Isolating receptors for IL-B30
I. GENERAL
The present invention provides amino acid sequences and DNA sequences encoding various mammalian proteins which are cytokines, e.g., which are secreted molecules which can mediate a signal between immune or other cells. See, e.g., Paul (1994)Fundamental Immunology (3d ed.) Raven Press, N.Y. The full length cytokines, and fragments, or antagonists will be useful in physiological modulation of cells expressing a receptor. It is likely that IL-B30 has either stimulatory or inhibitory effectson hematopoietic cells, including, e.g., lymphoid cells, such as T-cells, B-cells, natural killer (NK) cells, macrophages, dendritic cells, hematopoietic progenitors, etc. The proteins will also be useful as antigens, e.g., immunogens, for raisingantibodies to various epitopes on the protein, both linear and conformational epitopes.
A cDNA encoding IL-B30 was identified from a human cell line. The molecule was designated huIL-B30. A related gene corresponding to a pig sequence was also identified. A rodent sequence, e.g., from mouse, is also described.
The human gene encodes a small soluble cytokine-like protein, of about 168 amino acids. The signal sequence probably is about 21 residues, and would run from the Met to about Ala. See Table 1 and SEQ. ID. NO: 1 and 2. IL-B30 exhibitsstructural motifs characteristic of a member of the long chain cytokines. Compare, e.g., IL-B30, G-CSF, and IL-6, sequences available from GenBank. See also Table 2.
TABLE-US-00001 TABLE 1 Nucleic acid (SEQ ID NO: 1) encoding IL-B30 from a primate, e.g., human. Translated amino acid sequence is SEQ ID NO: 2. ATG CTG GGG AGC AGA GCT GTA ATG CTG CTG TTG CTG CTG CCC TGG ACA 48 Met Leu Gly Ser Arg Ala Val MetLeu Leu Leu Leu Leu Pro Trp Thr -21 -20 -15 -10 GCT CAG GGC AGA GCT GTG CCT GGG GGC AGC AGC CCT GCC TGG ACT CAG 96 Ala Gln Gly Arg Ala Val Pro Gly Gly Ser Ser Pro Ala Trp Thr Gln -5 1 5 10 TGC CAG CAG CTT TCA CAG AAG CTC TGC ACA CTG GCC TGG AGT GCA CAT144 Cys Gln Gln Leu Ser Gln Lys Leu Cys Thr Leu Ala Trp Ser Ala His 15 20 25 CCA CTA GTG GGA CAC ATG GAT CTA AGA GAA GAG GGA GAT GAA GAG ACT 192 Pro Leu Val Gly His Met Asp Leu Arg Glu Glu Gly Asp Glu Glu Thr 30 35 40 ACA AAT GAT GTT CCC CAT ATC CAG TGTGGA GAT GGC TGT GAC CCC CAA 240 Thr Asn Asp Val Pro His Ile Gln Cys Gly Asp Gly Cys Asp Pro Gln 45 50 55 GGA CTC AGG GAC AAC AGT CAG TTC TGC TTG CAA AGG ATC CAC CAG GGT 288 Gly Leu Arg Asp Asn Ser Gln Phe Cys Leu Gln Arg Ile His Gln Gly 60 65 70 75 CTGATT TTT TAT GAG AAG CTG CTA GGA TCG GAT ATT TTC ACA GGG GAG 336 Leu Ile Phe Tyr Glu Lys Leu Leu Gly Ser Asp Ile Phe Thr Gly Glu 80 85 90 CCT TCT CTG CTC CCT GAT AGC CCT GTG GCG CAG CTT CAT GCC TCC CTA 384 Pro Ser Leu Leu Pro Asp Ser Pro Val Ala Gln LeuHis Ala Ser Leu 95 100 105 CTG GGC CTC AGC CAA CTC CTG CAG CCT GAG GGT CAC CAC TGG GAG ACT 432 Leu Gly Leu Ser Gln Leu Leu Gln Pro Glu Gly His His Trp Glu Thr 110 115 120 CAG CAG ATT CCA AGC CTC AGT CCC AGC CAG CCA TGG CAG CGT CTC CTT 480 Gln Gln Ile ProSer Leu Ser Pro Ser Gln Pro Trp Gln Arg Leu Leu 125 130 135 CTC CGC TTC AAA ATC CTT CGC AGC CTC CAG GCC TTT GTG GCT GTA GCC 528 Leu Arg Phe Lys Ile Leu Arg Ser Leu Gln Ala Phe Val Ala Val Ala 140 145 150 155 GCC CGG GTC TTT GCC CAT GGA GCA GCA ACC CTGAGT CCC TAA 570 Ala Arg Val Phe Ala His Gly Ala Ala Thr Leu Ser Pro 160 165 coding sequence: ATGCTGGGGA GCAGAGCTGT AATGCTGCTG TTGCTGCTGC CCTGGACAGC TCAGGGCAGA GCTGTGCCTG GGGGCAGCAG CCCTGCCTGG ACTCAGTGCC AGCAGCTTTC ACAGAAGCTC TGCACACTGG CCTGGAGTGCACATCCACTA GTGGGACACA TGGATCTAAG AGAAGAGGGA GATGAAGAGA CTACAAATGA TGTTCCCCAT ATCCAGTGTG GAGATGGCTG TGACCCCCAA GGACTCAGGG ACAACAGTCA GTTCTGCTTG CAAAGGATCC ACCAGGGTCT GATTTTTTAT GAGAAGCTGC TAGGATCGGA TATTTTCACA GGGGAGCCTT CTCTGCTCCC TGATAGCCCT GTGGCGCAGCTTCATGCCTC CCTACTGGGC CTCAGCCAAC TCCTGCAGCC TGAGGGTCAC CACTGGGAGA CTCAGCAGAT TCCAAGCCTC AGTCCCAGCC AGCCATGGCA GCGTCTCCTT CTCCGCTTCA AAATCCTTCG CAGCCTCCAG GCCTTTGTGG CTGTAGCCGC CCGGGTCTTT GCCCATGGAG CAGCAACCCT GAGTCCCTAA Rodent, e.g., mouse, IL-B30 (SEQID NO: 3 and 4): CGCTTAGAAG TCGGACTACA GAGTTAGACT CAGAACCAAA GGAGGTGGAT AGGGGGTCCA 60 CAGGCCTGGT GCAGATCACA GAGCCAGCCA GATCTGAGAA GCAGGAACA AG ATG 115 Met -21 CTG GAT TGC AGA GCA GTA ATA ATG CTA TGG CTG TTG CCC TGG GTC ACT 163 Leu Asp Cys Arg Ala ValIle Met Leu Trp Leu Leu Pro Trp Val Thr -20 -15 -10 -5 CAG GGC CTG GCT GTG CCT AGG AGT AGC AGT CCT GAC TGG GCT CAG TGC 211 Gln Gly Leu Ala Val Pro Arg Ser Ser Ser Pro Asp Trp Ala Gln Cys 1 5 10 CAG CAG CTC TCT CGG AAT CTC TGC ATG CTA GCC TGG AAC GCA CATGCA 259 Gln Gln Leu Ser Arg Asn Leu Cys Met Leu Ala Trp Asn Ala His Ala 15 20 25 CCA GCG GGA CAT ATG AAT CTA CTA AGA GAA GAA GAG GAT GAA GAG ACT 307 Pro Ala Gly His Met Asn Leu Leu Arg Glu Glu Glu Asp Glu Glu Thr 30 35 40 AAA AAT AAT GTG CCC CGT ATC CAGTGT GAA GAT GGT TGT GAC CCA CAA 355 Lys Asn Asn Val Pro Arg Ile Gln Cys Glu Asp Gly Cys Asp Pro Gln 45 50 55 60 GGA CTC AAG GAC AAC AGC CAG TTC TGC TTG CAA AGG ATC CGC CAA GGT 403 Gly Leu Lys Asp Asn Ser Gln Phe Cys Leu Gln Arg Ile Arg Gln Gly 65 70 75CTG GCT TTT TAT AAG CAC CTG CTT GAC TCT GAC ATC TTC AAA GGG GAG 451 Leu Ala Phe Tyr Lys His Leu Leu Asp Ser Asp Ile Phe Lys Gly Glu 80 85 90 CCT GCT CTA CTC CCT GAT AGC CCC ATG GAG CAA CTT CAC ACC TCC CTA 499 Pro Ala Leu Leu Pro Asp Ser Pro Met Glu GlnLeu His Thr Ser Leu 95 100 105 CTA GGA CTC AGC CAA CTC CTC CAG CCA GAG GAT CAC CCC CGG GAG ACC 547 Leu Gly Leu Ser Gln Leu Leu Gln Pro Glu Asp His Pro Arg Glu Thr 110 115 120 CAA CAG ATG CCC AGC CTG ATG TCT AGT CAG CAG TGG CAG CGC CCC CTT 595 Gln Gln MetPro Ser Leu Ser Ser Ser Gln Gln Trp Gln Arg Pro Leu 125 130 135 140 CTC CGT TCC AAG ATC CTT CGA AGC CTC CAG GCC TTT TTG GCC ATA GCT 643 Leu Arg Ser Lys Ile Leu Arg Ser Leu Gln Ala Phe Leu Ala Ile Ala 145 150 155 GCC CGG GTC TTT GCC CAC GGA GCA GCA ACTCTG ACT GAG CCC TTA GTG 691 Ala Arg Val Phe Ala His Gly Ala Ala Thr Leu Thr Glu Pro Leu Val 160 165 170 CCA ACA GCT TAAGGATGCC CAGGTTCCCA TGGCTACCAT GATAAGACTA 740 Pro Thr Ala 175 ATCTATCAGC CCAGACATCT ACCAGTTAAT TAACCCATTA GGACTTGTGC TGTTCTTGTT 800TCGTTTGTTT TGCGTGAAGG GCAAGGACAC CATTATTAAA GAGAAAAGAA ACAAACCCCA 860 GAGCAGGCAG CTGGCTAGAG AAAGGAGCTG GAGAAGAAGA ATAAAGTCTC GAGCCCTTGG 920 CCTTGGAAGC GGGCAAGCAG CTGCGTGGCC TGAGGGGAAG GGGGCGGTGG CATCGAGAAA 980 CTGTGAGAAA ACCCAGAGCA TCAGAAAAAG TGAGCCCAGGCTTTGGCCAT TATCTGTAAG 1040 AAAAACAAGA AAAGGGGAAC ATTATACTTT CCTGGGTGGC TCAGGGAAAT GTGCAGATGC 1100 ACAGTACTCC AGACAGCAGC TCTGTACCTG CCTGCTCTGT CCCTCAGTTC TAACAGAATC 1160 TAGTCACTAA GAACTAACAG GACTACCAAT ACGAACTGAC AAA 1203MLDCRAVIMLWLLFWVTQGLAVPRSSSPDWAQCQQLSRNLCMLAWNAHAPAGHMNLLREEEDEETKNNV PRIQCEDGCDPQGLKDNSQFCLQRIRQGLAFYKHLLDSDIFKGEPALLPDSPMEQLHTSLLGLSQLLQP EDHPRETQQNPSLSSSQQWQRPLLRSKILRSLQAFLAIAARVFAHGAATLTEPLVPTA
TABLE-US-00002 TABLE 2 Comparison of various IL-6 and G-CSF embodiments compared to IL-B30. Human IL-B30 is SEQ ID NO: 2; mouse IL-B30 is SEQ ID NO: 4; pig IL-B30 is SEQ ID NO: 5; bovine G-CSF is SEQ ID NO: 6; feline G-CSF is SEQ ID NO: 7;human G-CSF is SEQ ID NO: 8; mouse G-CSF is SEQ ID NO: 9; otter IL-6 is SEQ ID NO: 10; feline IL-6 is SEQ ID NO: 11; human IL-6 is SEQ ID NO: 12; sheep IL-6 is SEQ ID NO: 13; mouse IL-6 is SEQ ID NO: 14; chicken MGF is SEQ ID NO: 15; and KSHV, kaposi'ssarcoma herpes virus, a viral IL-6, is SEQ ID NO: 16. i130_human .......... ......VPGG SSPVWTQCQQ LSQKLCT.LA WSAHPLVG.. i130_mouse .......... ......VPRS SSPDWAQCQQ LSRNLCM.LA WNAHAPAG.. i130_pig .......... .......... .......... .................... gcsf_bovin ......TPLG P.......AR SLPQSFLLKC LEQVRKIQAD GAELQERL.. gcsf_felca ......TPLG P.......TS SLPQSFLLKC LEQVRKVQAD GTALQERL.. gcsf_human ......TPLG P.......AS SLPQSFLLKC LEQVRKIQGD GAALQEKLVS gcsf_mouse VPLVTVSALP P.......SL PLPRSFLLKSLEQVRKIQAS GSVLLEQL.. i16_otter .AFPTPGPLP GDSKDDATSN RPPLTSADKM EDFIKFILGK ISALRNEM.. i16_felca .AFPTPGPLG G....DATSN RLPLTPADKM EELIKYILGK ISALKKEM.. i16_human .AFPAPVPPG EDSKDVAAPH RQPLTSSERI DKQIRYILDG ISALRKET.. i16_sheep .AFPTPGPLG EDFKNDTTPSRLLLTTPEKT EALIKHIVDK ISAIRKEI.. i16_mouse .AFPTSQVRR GDFTEDTTPN R.PVYTTSQV GGLITHVLWE IVEMRKEL.. mgf_chick .......... .APLAELSGD HDFQLFLHKN LEFTRKIRGD VAALQRAV.. i16_khsv .......... .......TRG KLPDAPEFEK DLLIQRLNWM LWVIDECFRD i130_human .HMD.LREEGDEETTNDVPH I...QCGDGC DPQGLRDNSQ FCLQRIHQGL i130_mouse .HMNLLREEE DEETKNNVPR I...QCEDGC DPQGLKDNSQ FCLQRIRQGL i130_pig .......... .......... .......... .......... SCLQRIHQGL gcsf_bovin .CAA.HKLCH PEELMLLRHS LGIP.QAPLS SCSSQSLQLR GCLNQLHGGL gcsf_felca.CAA.HKLCH PEELVLLGHA LGIP.QAPLS SCSSQALQLT GCLRQLHSGL gcsf_human ECAT.YKLCH PEELVLLGHS LGIP.WAPLS SCPSQALQLA GCLSQLHSGL gcsf_mouse .CAT.YKLCH PEELVLLGHS LGIP.KASLS GCSSQALQQT QCLSQLHSGL i16_otter .CDK.YNKCE DSKEVLAENN LNLPKLAEKD RCFQSRFNQE TCLTRITTGLi16_felca .CDN.YNKCE DSKEALAENN LNLPKLAEKD GCFQSGFNQE TCLTRITTGL i16_human .CNK.SNMCE SSKEALAENN LNLPKMAEKD GCFQSGFNEE TCLVKIITGL i16_sheep .CEK.NDECE NSKETLAENK LKLPKMEEKD GCFQSGFNQA ICLIKTTAGL i16_mouse .CNG.NSDCM NNDDALAENN LKLPEIQRND GCYQTGYNQEICLLKISSGL mgf_chick .CDT.FQLCT EEELQLVQPD PHLV.QAPLD QCHKRGFQAE VCFTQIRAGL i16_khsv LCYR.TGICK GILEPAAIFH LKLPAINDTD HCGLIGFNET SCLKKLADGF i130_human IFYEKLLGSD IFTGE..... .PSLLPDSPV AQLHASLLGL SQLLQPE..C i130_mouse AFYKHLLDSD IFKGE..... .PALLPDSPMEQLHTSLLGL SQLLQPE..D i130_pig VFYEKLLGSD IFTGE..... .PSLHPDGSV GQLHASLLGL RQLLQPE..G gcsf_bovin FLYQGLLQAL AGIS...... .PELAPTLDT LQLDVTDFAT NIWLQMEDLG gcsf_felca FLYQGLLQAL AGIS...... .PELAPTLDM LQLDITDFAI NIWQQMEDVG gcsf_human FLYQGLLQAL EGIS...... .PELGFTLDT LQLDVADFAT TIWQQMEELG gcsf_mouse CLYQGLLQAL SGIS...... .PALAPTLDL LQLDVANFAT TIWQQMENLG i16_otter QEFQIHLKYL ESNYEG...N KDNAHSVYIS TKHLLQTLRP M..NQIEVTT i16_felca QEFQIYLKFL QDKYEG...D KENAKSVYTS TNVLLQMLKR KGKNQDEVTI i16_human LEFEVYLEYLQNRFES...S EEQARAVQMS TKVLIQFLQK KAKNLDAITT i16_sheep LEYQIYLDFL QNEFEG...N QETVMELQSS IRTLIQILKE KIAGL....I i16_mouse LEYHSYLEYM KNNLKDN..K KDKARVLQRD TETLIHIFNQ EVKDLHKIVL mgf_chick HAYHDSLGAV LRLLP..... ..NHTTLVET LQLDAANLSS NIQQQMEDLG i16_khsvFEFEVLFKFL TTEFGKSVIN VDVMELLTKT LGWDIQEELN KLTKTHY..S i130_human HHWETQQIP. .SLSPSQ..P WQRLLLRFKI LRSLQAFVAV AARVFAHGAA i130_mouse HPRETQQMP. .SLSSSQ..Q WQRPLLRSKI LRSLQAFLAI AARVFAHGAA i130_pig HHWETEQTP. .SPSPSQ..P WQRLLLRLKI LRSLQAFVAV AARVFAHGAAgcsf_bovin AAPAVQPTQ. .GAMPTFTSA FQRRAGGVLV ASQLHRFLEL AYRGLRYLAE gcsf_felca MAPAVPPTQ. .GTMPTFTSA FQRRAGGTLV ASNLQSFLEV AYRALRHFTK gcsf_human MAPALQPTQ. .GAMPAFASA FQRRAGGVLV ASHLQSFLEV SYRVLRHLAQ gcsf_mouse VAPTVQPTQ. .SAMPAFTSA FQRRAGGVLAISYLQGFLET ARLALHHLA. i16_otter PDPTTDASL. .QALFKSQDK WLKHTTIHLI LRRLEDFLQF SLRAIRIM.. i16_felca PVPTVEVGL. .QLSCSHR.R VAEAHNNHLT LRRLEDFLQL RLRAVRIM.. i16_human PDPTTNASL. .LTKLQAQNQ WLQDHTTHLI LRSPKEFLQS SLRALRQM.. i16_sheep TTPATHTDM. .LEKMQSSNE WVKNAKVIII LRSLENFLQF SLRAIRMK.. i16_mouse PTPISNALL. .TDKLESQKE WLRTKTIQFI LKSLEEFLKV TLRSTRQT.. mgf_chick LDTVTLPAEQ RSPPPTFSGP FQQQVGGFFI LANFQRFLET AYRALRHLAR i16_khsv P.PKFDRG.. LLGRLQGLKY WVRHFASFYV LSAMEKPAGQ AVRVLDSIPD i130_humanTLSP.... i130_mouse TLTEPLVPTA i130_pig TLSQ.... gcsf_bovin P....... gcsf_felca P....... gcsf_human P....... gcsf_mouse ........ i16_otter ........ i16_felca ........ i16_human ........ i16_sheep ........ i16_mouse ........ mgf_chick L....... i16_khsv VTPDVHDK
I. General Methods
Many of the standard methods below are described or referenced, e.g., in Maniatis, et al. (1982) Molecular Cloning, A Laboratory Manual Cold Spring Harbor Laboratory, Cold Spring Harbor Press, NY; Sambrook, et al. (1989) Molecular Cloning: ALaboratory Manual (2d ed.) Vols. 1-3, CSH Press, NY; Ausubel, et al., Biology Greene Publishing Associates, Brooklyn, N.Y.; or Ausubel, et al. (1987 and Supplements) Current Protocols in Molecular Biology Wiley/Greene, NY; Innis, et al. (eds. 1990) PCRProtocols: A Guide to Methods and Applications Academic Press, NY. Methods for protein purification include such methods as ammonium sulfate precipitation, column chromatography, electrophoresis, centrifugation, crystallization, and others. See, e.g.,Ausubel, et al. (1987 and periodic supplements); Deutscher (1990) "Guide to Protein Purification," Methods in Enzymology vol. 182, and other volumes in this series; Coligan, et al. (1995 and supplements) Current Protocols in Protein Science John Wileyand Sons, New York, N.Y.; P. Matsudaira (ed. 1993) A Practical Guide to Protein and Peptide Purification for Microsequencing, Academic Press, San Diego, Calif.; and manufacturer's literature on use of protein purification products, e.g., Pharmacia,Piscataway, N.J., or Bio-Rad, Richmond, Calif. Combination with recombinant techniques allow fusion to appropriate segments (epitope tags), e.g., to a FLAG sequence or an equivalent which can be fused, e.g., via a protease-removable sequence. See,e.g., Hochuli (1989) Chemische Industrie 12:69-70; Hochuli (1990) "Purification of Recombinant Proteins with Metal Chelate Absorbent" in Setlow (ed.) Genetic Engineering Principle and Methods 12:87-98, Plenum Press, NY; and Crowe, et al. (1992)OIAexpress: The High Level Expression & Protein Purification System QUIAGEN, Inc., Chatsworth, Calif.
Standard immunological techniques are described, e.g., in Hertzenberg, et al. (eds. 1996) Weir's Handbook of Experimental Immunology vols. 1-4, Blackwell Science; Coligan (1991) Current Protocols in Immunology Wiley/Greene, NY; and Methods inEnzymology vols. 70, 73, 74, 84, 92, 93, 108, 116, 121, 132, 150, 162, and 163. Cytokine assays are described, e.g., in Thomson (ed. 1994) The Cytokine Handbook (2d ed.) Academic Press, San Diego; Metcalf and Nicola (1995) The Hematopoietic ColonyStimulating Factors Cambridge University Press; and Aggarwal and Gutterman (1991) Human Cytokines Blackwell Pub. Assays for vascular biological activities are well known in the art. They will cover angiogenic and angiostatic activities in tumor, orother tissues, e.g., arterial smooth muscle proliferation (see, e.g., Koyoma, et al. (1996) Cell 87:1069-1078), monocyte adhesion to vascular epithelium (see McEvoy, et al. (1997) J. Exp. Med. 185:2069-2077), etc. See also Ross (1993) Nature362:801-809; Rekhter and Gordon (1995) Am. J. Pathol. 147:668-677; Thyberg, et al. (1990) Atherosclerosis 10:966-990; and Gumbiner (1996) Cell 84:345-357.
Assays for neural cell biological activities are described, e.g., in Wouterlood (ed. 1995) Neuroscience Protocols modules 10, Elsevier; Methods in Neuroscieces Academic Press; and Neuromethods Humana Press, Totowa, N.J. Methodology ofdevelopment systems is described, e.g., in Meisami (ed.) Handbook of Human Growth and Developmental Bioloy CRC Press; and Chrispeels (ed.) Molecular Techniques and Approaches in Developmental Biology Interscience.
FACS analyses are described in Melamed, et al. (1990) Flow Cytometry and Sortina Wiley-Liss, Inc., New York, N.Y.; Shapiro (1988) Practical Flow Cytometry Liss, New York, N.Y.; and Robinson, et al. (1993) Handbook of Flow Cytometry MethodsWiley-Liss, New York, N.Y.
II. Cloning of Human IL-B30
The sequence of the gene is provided in Table 1. The sequence is derived from a cDNA library made from melanocyte, fetal heart, and pregnant uterus. It is also found from a cDNA library sequence derived from a pancreatic islet. These sequencesallow preparation of PCR primers, or probes, to determine cellular distribution of the gene. The sequences allow isolation of genomic DNA which encode the message.
Using the probe or PCR primers, various tissues or cell types are probed to determine cellular distribution. PCR products are cloned using, e.g., a TA cloning kit (Invitrogen). The resulting cDNA plasmids are sequenced from both termini on anautomated sequencer (Applied Biosystems).
III. Cellular Expression of IL-B30
An appropriate probe or primers specific for cDNA encoding primate IL-B30 are prepared. Typically, the probe is labeled, e.g., by random priming. The expression is probably in the cell types described, and perhaps also in pancreatic islets. Southern Analysis: DNA (5 .mu.g) from a primary amplified cDNA library was digested with appropriate restriction enzymes to release the inserts, run on a 1% agarose gel and transferred to a nylon membrane (Schleicher and Schuell, Keene, N.H.).
Samples for human mRNA isolation include: peripheral blood mononuclear cells (monocytes, T cells, NK cells, granulocytes, B cells), resting (T100); peripheral blood mononuclear cells, activated with anti-CD3 for 2, 6, 12 h pooled (T101); T cell,TH0 clone Mot 72, resting (T102); T cell, TH0 clone Mot 72, activated with anti-CD28 and anti-CD3 for 3, 6, 12 h pooled (T103); T cell, TH0 clone Mot 72, anergic treated with specific peptide for 2, 7, 12 h pooled (T104); T cell, TH1 clone HY06, resting(T107); T cell, TH1 clone HY06, activated with anti-CD28 and anti-CD3 for 3, 6, 12 h pooled (T108); T cell, TH1 clone HY06, anergic treated with specific peptide for 2, 6, 12 h pooled (T109); T cell, TH2 clone HY935, resting (T110); T cell, TH2 cloneHY935, activated with anti-CD28 and anti-CD3 for 2, 7, 12 h pooled (T111); T cell tumor lines Jurkat and Hut78, resting (T117); T cell clones, pooled AD130.2, Tc783.12, Tc783.13, Tc783.58, Tc782.69, resting (T118); T cell random .gamma..delta. T cellrandom .gamma..delta. T cell clones, resting (Tll9); CD28-T cell clone; Splenocytes, resting (B100); Splenocytes, activated with anti-CD40 and IL-4 (B100); B cell EBV lines pooled WT49, RSB, JY, CVIR, 721.221, RM3, HSY, resting (B102); B cell line JY,activated with PMA and ionomycin for 1, 6 h pooled (B103); NK 20 clones pooled, resting (K100); NK 20 clones pooled, activated with PMA and ionomycin for 6 h (K101); NKL clone, derived from peripheral blood of LGL leukemia patient, IL-2 treated (K106);hematopoietic precursor line TF1, activated with PMA and ionomycin for 1, 6 h pooled (C100); U937 premonocytic line, resting (M100); U937 premonocytic line, activated with PMA and ionomycin for 1, 6 h pooled (M101); elutriated monocytes, activated withLPS, IFN.gamma., anti-IL-10 for 1, 2, 6, 12, 24 h pooled (M102); elutriated monocytes, activated with LPS, IFN.gamma., IL-10 for 1, 2, 6, 12, 24 h pooled (M103); elutriated monocytes, activated with LPS, IFN.gamma., anti-IL-10 for 4, 16 h pooled (M106);elutriated monocytes, activated with LPS, IFN.gamma., IL-10 for 4, 16 h pooled (M107); elutriated monocytes, activated LPS for 1 h (M108); elutriated monocytes, activated LPS for 6 h (M109); DC 70% CD1a+, from CD34+ GM-CSF, TNF.alpha. 12 days, resting(D101); DC 70% CD1a+, from CD34+ GM-CSF, TNF.alpha. 12 days, activated with PMA and ionomycin for 1 hr (D102); DC 70% CD1a+, from CD34+ GM-CSF, TNF.alpha. 12 days, activated with PMA and ionomycin for 6 hr (D103); DC 95% CD1a+, from CD34+ GM-CSF,TNF.alpha. 12 days FACS sorted, activated with PMA and ionomycin for 1, 6 h pooled (D104); DC 95% CD14+, ex CD34+ GM-CSF, TNF.alpha. 12 days FACS sorted, activated with PMA and ionomycin 1, 6 hr pooled (D105); DC CD1a+ CD86+, from CD34+ GM-CSF,TNF.alpha. 12 days FACS sorted, activated with PMA and ionomycin for 1, 6 h pooled (D106); DC from monocytes GM-CSF, IL-4 5 days, resting (D107); DC from monocytes GM-CSF, IL-4 5 days, resting (D108); DC from monocytes GM-CSF, IL-4 5 days, activated LPS4, 16 h pooled (D109); DC from monocytes GM-CSF, IL-4 5 days, activated TNF.alpha., monocyte supe for 4, 16 h pooled (D110); epithelial cells, unstimulated; epithelial cells, IL-1.beta. activated; lung fibroblast sarcoma line MRC5, activated with PMAand ionomycin for 1, 6 h pooled (C101); kidney epithelial carcinoma cell line CHA, activated with PMA and ionomycin for 1, 6 h pooled (C102). Expression of IL-B30 transcript was very high in elutriated monocytes, activated with LPS, IFN.gamma.,anti-IL-10 for 4, 16 h pooled (M106); elutriated monocytes, activated with LPS, IFN.gamma., anti-IL-10 for 1, 2, 6, 12, 24 h pooled (M102); elutriated monocytes, activated LPS for 6 h (M109); and elutriated monocytes, activated LPS for 1 h (M108). Expression was high in DC 95% CD1a+, from CD34+ GM-CSF, TNF.alpha. 12 days FACS sorted, activated with PMA and ionomycin for 1, 6 h pooled (D104); and NK 20 clones pooled, activated with PMA and ionomycin for 6 h (K101). Lesser expression was detectedin DC 70% CD1a+, from CD34+ GM-CSF, TNF.alpha. 12 days, activated with PMA and ionomycin for 6 hr (D103); DC 70% CD1a+, from CD34+ GM-CSF, TNF.alpha. 12 days, activated with PMA and ionomycin for 1 hr (D102) ; T cell, TH1 clone HY06, anergic treatedwith specific peptide for 2, 6, 12 h pooled (T109); peripheral blood mononuclear cells, activated with anti-CD3 for 2, 6, 12 h pooled (T101); T cell, TH0 clone Mot 72, activated with anti-CD28 and anti-CD3 for 3, 6, 12 h pooled (T103); Splenocytes,activated with anti-CD40 and IL-4 (B101); T cell, TH0 clone Mot 72, anergic treated with specific peptide for 2, 7, 12 h pooled (T104); Splenocytes, resting (B100); T cell, TH1 clone HY06, activated with anti-CD28 and anti-CD3 for 3, 6, 12 h pooled(T108); epithelial cells, IL-1.beta. activated; elutriated monocytes, activated with LPS, IFN.gamma., IL-10 for 4, 16 h pooled (M107); and B cell line JY, activated with PMA and ionomycin for 1, 6 h pooled (B103). Detectable expression was observed inDC from monocytes GM-CSF, IL-4 5 days, activated LPS 4, 16 h pooled (D109); T cell, TH0 clone Mot 72, resting (T102); peripheral blood mononuclear cells (monocytes, T cells, NK cells, granulocytes, B cells), resting (T100); T cells CD4+ CD45RO- T cellspolarized 27 days in anti-CD28, IL-4, and anti IFN-.gamma., TH2 polarized, activated with anti-CD3 and anti-CD28 4 h (T116); T cell clones, pooled AD130.2, Tc783.12, Tc783.13, Tc783.58, Tc782.69, resting (T118); U937 premonocytic line, resting (M100);hematopoietic precursor line TF1, activated with PMA and ionomycin for 1, 6 h pooled (C100); T cell, Th2 clone HY935, activated with anti-CD28 and anti-CD3 for 2, 7, 12 h pooled (T111); DC Cd1a+ CD86+, from CD34+ GM-CSF, TNF.alpha. 12 days FACS sorted,activated with PMA and ionomycin for 1, 6 h pooled (D106); elutriated monocytes, activated with LPS, IFN.gamma., IL-10 for 1, 2, 6, 12, 24 h pooled (M103); DC from monocytes GM-CSF, IL-4 5 days, activated TNF.alpha., monocyte supe for 4, 16 h pooled(D110); DC from monocytes GM-CSF, IL-4 5 days, resting (D108); U937 premonocytic line, activated with PMA and ionomycin for 1, 6 h pooled (M101); T cell random .gamma..delta. cell clones, resting (T119); and T cell, TH1 clone HY06, activated withanti-CD28 and anti-CD3 for 3, 6, 12 h pooled (T108). No signal was detected in the other samples.
In summary, the distribution shows IL-B30 elevated in activated macrophages, suggesting a role in inflammation; activated Th1 cells, suggesting a regulation or effector role in T helper subsets, particularly Th1 immune responses; and activateddendritic cells, suggesting a role in antigen presentation or germinal center T or B cell interactions with DC.
Samples for mouse mRNA isolation include: resting mouse fibroblastic L cell line (C200); Braf:ER (Braf fusion to estrogen receptor) transfected cells, control (C201); Me114+ naive T cells from spleen, resting (T209); Mel14+ naive T cells fromspleen, stimulated with IFN.gamma., IL-12, and anti IL-4 to polarize to TH1 cells, exposed to IFN.gamma. and IL-4 for 6, 12, 24 h, pooled (T210); Mel14+ naive T cells from spleen, stimulated with IL-4 and anti IFN.gamma. to polarize to Th2 cells,exposed to IL-4 and anti IFN.gamma. for 6, 13, 24 h, pooled (T211); T cells, TH1 polarized (Mel14 bright, CD4+ cells from spleen, polarized for 7 days with IFN-.gamma. and anti IL-4; T200); T cells, TH2 polarized (Mel14 bright, CD4+ cells from spleen,polarized for 7 days with IL-4 and anti-IFN-.gamma.; T201); T cells, highly TH1 polarized 3.times. from transgenic Balb/C (see Openshaw, et al. (1995) J. Exp. Med. 182:1357-1367; activated with anti-CD3 for 2, 6, 24 h pooled; T202); T cells, highlyTH2 polarized 3.times. from transgenic Balb/C (activated with anti-CD3 for 2, 6, 24 h pooled (T203); T cells, highly TH1 polarized 3.times. from transgenic C57 bl/6 (activated with anti-CD3 for 2, 6, 24 h pooled; T212); T cells, highly TH2 polarized3.times. from transgenic C57 bl/6 (activated with anti-CD3 for 2, 6, 24 h pooled; T213); T cells, highly TH1 polarized (naive CD4+ T cells from transgenic Balb/C, polarized 3.times. with IFN.gamma., IL-12, and anti-IL-4; stimulated with IGIF, IL-12,and anti IL-4 for 6, 12, 24 h, pooled); CD44- CD25+ pre T cells, sorted from thymus (T204); TH1 T cell clone D1.1, resting for 3 weeks after last stimulation with antigen (T205); TH1 T cell clone D1.1, 10 .mu.g/ml ConA stimulated 15 h (T206); TH2 T cellclone CDC35, resting for 3 weeks after last stimulation with antigen (T207); TH2 T cell clone CDC35, 10 .mu.g/ml ConA stimulated 15 h (T208); unstimulated B cell line CH12 (B201); unstimulated mature B cell leukemia cell line A20 (B200); unstimulatedlarge B cells from spleen (B202); B cells from total spleen, LPS activated (B203); metrizamide enriched dendritic cells from spleen, resting (D200); dendritic cells from bone marrow, resting (D201); unstimulated bone marrow derived dendritic cellsdepleted with anti B220, anti CD3, and anti Class II, cultured in GM-CSF and IL-4 (D202); bone marrow derived dendritic cells depleted with anti B220, anti CD3, and anti Class II, cultured in GM-CSF and IL-4, stimulated with anti CD40 for 1,5 d, pooled(D203); monocyte cell line RAW 264.7 activated with LPS 4 h (M200); bone-marrow macrophages derived with GM and M-CSF (M201); bone-marrow macrophages derived with GM-CSF, stimulated with LPS, IFN.gamma., and IL-10 for 24 h (M205); bone-marrow macrophagesderived with GM-CSF, stimulated with LPS, IFN.gamma., and anti IL-10 for 24 h (M206); peritoneal macrophages (M207); macrophage cell line J774, resting (M202); macrophage cell line J774+LPS+anti-IL-10 at 0.5, 1, 3, 6, 12 h pooled (M203); macrophage cellline J774+LPS+IL-10 at 0.5, 1, 3, 5, 12 h pooled (M204); unstimulated mast cell lines MC-9 and MCP-12 (M208); immortalized endothelial cell line derived from brain microvascular endothelial cells, unstimulated (E200); immortalized endothelial cell linederived from brain microvascular endothelial cells, stimulated overnight with TNF.alpha. (E201); immortalized endothelial cell line derived from brain microvascular endothelial cells, stimulated overnight with TNF.alpha. (E202); immortalizedendothelial cell line derived from brain microvascular endothelial cells, stimulated overnight with TNF.alpha. and IL-10 (E203); total aorta from wt C57 bl/6 mouse; total aorta from 5 month ApoE KO mouse (X207); total aorta from 12 month ApoE KO mouse(X207); wt thymus (O214); total thymus rag-1 (O208); total kidney, rag-1 (O209); total kidney, NZ B/W mouse; and total heart, rag-1 (O202). High signal was detected in the monocyte cell line RAW 264.7 activated with LPS 4 h (M200); T cells, highly TH1polarized 3.times. from transgenic C57 bl/6 (activated with anti-CD3 for 2, 6, 24 h pooled; T212); and T cells, highly TH1 polarized (naive CD4+ T cells from transgenic Balb/C, polarized 3.times. with IFN.gamma., IL-12, and anti-IL-4; stimulated withIGIF, IL-12, and anti IL-4 for 6, 12, 24 h, pooled). Detectable signals were detected in T cells, highly TH1 polarized 3.times. from transgenic Balb/C (see Openshaw, et al. (1995) J. Exp. Med. 182:1357-1367; activated with anti-CD3 for 2, 6, 24 hpooled; T202); T cells, TH2 polarized (Mel14 bright, CD4+ cells from spleen, polarized for 7 days with IL-4 and anti-IFN-.gamma., T201); T cells, TH1 polarized (Mel14 bright, CD4+ cells from spleen, polarized for 7 days with IFN-.gamma. and anti IL-4;T200); macrophage cell line J774+LPS+anti-IL-10 at 0.5, 1, 3, 6, 12 h pooled (M203); macrophage cell line J774, resting (M202); macrophage cell line J774+LPS+IL-10 at 0.5, 1, 3, 5, 12 h pooled (M204); immortalized endothelial cell line derived from brainmicrovascular endothelial cells, stimulated overnight with TNF.alpha. (E201); and bone-marrow macrophages derived with GM-CSF, stimulated with LPS, IFN.gamma., and anti IL-10 for 24 h (M206). Other samples showed no signal. The expression in the RAW264.7 mouse monocyte cell line suggests a natural source for protein.
IV. Chromosome mapping of IL-B30
An isolated cDNA encoding the IL-B30 is used. Chromosome mapping is a standard technique. See, e.g., BIOS Laboratories (New Haven, Conn.) and methods for using a mouse somatic cell hybrid panel with PCR. Circumstantial evidence suggests thatthe mouse gene is localized on chromosome 10.
V. Purification of IL-B30 Protein
Multiple transfected cell lines are screened for one which expresses the cytokine at a high level compared with other cells. Various cell lines are screened and selected for their favorable properties in handling. Natural IL-B30 can be isolatedfrom natural sources, or by expression from a transformed cell using an appropriate expression vector. Purification of the expressed protein is achieved by standard procedures, or may be combined with engineered means for effective purification at highefficiency from cell lysates or supernatants, FLAG or His.sub.6 segments can be used for such purification features. Alternatively, affinity chromatography may be used with specific antibodies, see below.
Protein is produced in coli, insect cell, or mammalian expression systems, as desired.
VI. Isolation of Homologous IL-B30 Genes
The IL-B30 cDNA, or other species counterpart sequence, can be used as a hybridization probe to screen a library from a desired source, e.g., a primate cell cDNA library. Many different species can be screened both for stringency necessary foreasy hybridization, and for presence using a probe. Appropriate hybridization conditions will be used to select for clones exhibiting specificity of cross hybridization.
Screening by hybridization using degenerate probes based upon the peptide sequences will also allow isolation of appropriate clones. Alternatively, use of appropriate primers for PCR screening will yield enrichment of appropriate nucleic acidclones.
Similar methods are applicable to isolate either species, polymorphic, or allelic variants. Species variants are isolated using cross-species hybridization techniques based upon isolation of a full length isolate or fragment from one species asa probe.
Alternatively, antibodies raised against human IL-B30 will be used to screen for cells which express cross-reactive proteins from an appropriate, e.g., cDNA library. The purified protein or defined peptides are useful for generating antibodiesby standard methods, as described above. Synthetic peptides or purified protein are presented to an immune system to generate monoclonal or polyclonal antibodies. See, e.g., Coligan (1991) Current Protocols in Immunology Wiley/Greene; and Harlow andLane (1989) Antibodies: A Laboratory Manual Cold Spring Harbor Press. The resulting antibodies are used for screening, purification, or diagnosis, as described.
VII. Preparation of antibodies specific of IL-B30
Synthetic peptides or purified protein are presented to an immune system to generate monoclonal or polyclonal antibodies. See, e.g., Coligan (1991) Current Protocols in Immunology Wiley/Greene; and Harlow and Lane (1989) Antibodies: A LaboratoryManual Cold Spring Harbor Press. Polyclonal serum, or hybridomas may be prepared. In appropriate situations, the binding reagent is either labeled as described above, e.g., fluorescence or otherwise, or immobilized to a substrate for panning methods. Immunoselection and related techniques are available to prepare selective reagents, as desired.
VIII. Evaluation of Breadth of Biological Functions
Biological activities of IL-B30 were tested based on the sequence and structural homology between IL-B30 and IL-6 and G-CSF. Initially, assays that had shown biological activities of IL-6 or G-CSF are examined.
A. Effects on proliferation of cells
The effect on proliferation of various cell types are evaluated with various concentrations of cytokine. A dose response analysis is performed, in combinations with the related cytokines IL-6, G-CSF, etc.
B. Effects on the expression of cell surface molecules on human monocytes
Monocytes are purified by negative selection from peripheral blood mononuclear cells of normal healthy donors. Briefly, 3.times.10.sup.8 ficoll banded mononuclear cells are incubated on ice with a cocktail of monoclonal antibodies(Becton-Dickinson; Mountain View, Calif.) consisting, e.g., of 200 .mu.l Dickinson; Mountain View, Calif.) consisting, e.g., of 200 .mu.l of .alpha.CD2 (Leu-5A), 200 .mu.l of .alpha.CD3 (Leu-4), 100 .mu.l of .alpha.CD8 (Leu 2a), 100 .mu.l of .alpha.CD19(Leu-12), 100 .mu.l of .alpha.CD20 (Leu-16), 100 .mu.l of .alpha.CD56 (Leu-19), 100 .mu.l of .alpha.CD67 (IOM 67; Immunotech, Westbrook, Me.), and anti-glycophorin antibody (10F7MN, ATCC, Rockville, Md.). Antibody bound cells are washed and thenincubated with sheep anti-mouse IgG coupled magnetic beads (Dynal, Oslo, Norway) at a bead to cell ratio of 20:1. Antibody bound cells are separated from monocytes by application of a magnetic field. Subsequently, human monocytes are cultured inYssel's medium (Gemini Bioproducts, Calabasas, Calif.) containing 1% human AB serum in the absence or presence of IL-B30, IL-6, G-CSF or combinations.
Analyses of the expression of cell surface molecules can be performed by direct immunoflorescence. For example, 2.times.10.sup.5 purified human monocytes are incubated in phosphate buffered saline (PBS) containing 1% human serum on ice for 20minutes. Cells are pelleted at 200.times.g. Cells are resuspended in 20 ml PE or FITC labeled mAb. Following an additional 20 minute incubation on ice, cells are washed in PBS containing 1% human serum followed by two washes in PBS alone. Cells arefixed in PBS containing 1% paraformaldehyde and analyzed on FACScan flow cytometer (Becton Dickinson; Mountain View, Calif.). Exemplary mAbs are used, e.g.: CD11b (anti-mac1), CD11c (a gp150/95), CD14 (Leu-M3), CD54 (Leu 54), CD80 (anti-BB1/B7), HLA-DR(L243) from Becton-Dickinson and CD86 (FUN 1; Pharmingen), CD64 (32.2; Medarex), CD40 (mAb89; Schering-Plough France).
C. Effects of IL-B30 on cytokine production by human monocytes
Human monocytes are isolated as described and cultured in Yssel's medium (Gemini Bioproducts, Calabasas, Calif.) containing 1% human AB serum in the absence or presence of IL-B30 (1/100 dilution baculovirus expressed material). In addition,monocytes are stimulated with LPS (E. coli 0127:B8 Difco) in the absence or presence of IL-B30 and the concentration of cytokines (IL-1.beta., IL-6, TNF.alpha., GM-CSF, and IL-10) in the cell culture supernatant determined by ELISA.
For intracytoplasmic staining for cytokines, monocytes are cultured (1 million/ml) in Yssel's medium in the absence or presence of IL-B30 and LPS (E. coli 0127:B8 Difco) and 10 mg/ml Brefeldin A (Epicentre technologies Madison Wis.) for 12 hrs. Cells are washed in PBS and incubated in 2% formaldehyde/PBS solution for 20 minutes at RT. Subsequently cells are washed, resuspended in permeabilization buffer (0.5% saponin/(Sigma) in PBS/BSA (0.5%)/Azide (1 mM)) and incubated for 20 minutes at RT. Cells (2.times.10.sup.5) are centrifuged and resuspended in 20 ml directly conjugated anti-cytokine mAbs diluted 1:10 in permeabilization buffer for 20 minutes at RT. The following antibodies can be used: IL-1.alpha.-PE (364-3B3-14); IL-6-PE (MQ2-13A5);TNF.alpha.-PE (MAb11); GM-CSF-PE (BVD2-21C11); and IL-12-PE (C11.5.14; Pharmingen San Diego, Calif.). Subsequently, cells are washed twice in permeabilization buffer and once in PBS/BSA/Azide and analyzed on FACScan flow cytometer (Becton Dickinson;Mountain View, Calif.).
D. Effects of IL-B30 on proliferation of human peripheral blood mononuclear cells (PBMC).
Total PBMC are isolated from buffy coats of normal healthy donors by centrifugation through ficoll-hypaque as described (Boyum, et al.). PBMC are cultured in 200 .mu.l Yssel's medium (Gemini Bioproducts, Calabasas, Calif.) containing 1% human ABserum in 96 well plates (Falcon, Becton-Dickinson, N.J.) in the absence or presence of IL-B30. Cells are cultured in medium alone or in combination with 100 U/ml IL-2 (R&D Systems) for 120 hours. 3H-Thymidine (0.1 mCi) is added during the last sixhours of culture and 3H-Thymidine incorporation determined by liquid scintillation counting.
The native, recombinant, and fusion proteins would be tested for agonist and antagonist activity in many other biological assay systems, e.g., on T-cells, B-cells, NK, macrophages, dendritic cells, hematopoietic progenitors, etc. Because of theIL-6 and G-CSF structural relationship, assays related to those activities should be analyzed
IL-B30 is evaluated for agonist or antagonist activity on transfected cells expressing IL-6 or G-CSF receptor and controls. See, e.g., Ho, et al. (1993) Proc. Nat'l Acad. Sci. USA 90, 11267-11271; Ho, et al. (1995) Mol. Cell. Biol. 15:5043-5053; and Liu, et al. (1994). J. Immunol. 152:1821-1829.
IL-B30 is evaluated for effect in macrophage/dendritic cell activation and antigen presentation assays, T cell cytokine production and proliferation in response to antigen or allogeneic stimulus. See, e.g., de Waal Malefyt et al. (1991) J. Exp. Med. 174:1209-1220; de Waal Malefyt et al. (1991) J. Exp. Med. 174:915-924; Fiorentino, et al. (1991) J. Immunol. 147, 3815-3822; Fiorentino, et al. (1991) J. Immunol. 146:3444-3451; and Groux, et al. (1996) J. Exp. Med. 184:19-29.
IL-B30 will also be evaluated for effects on NK cell stimulation. Assays may be based, e.g., on Hsu, et al. (1992) Internat. Immunol. 4:563-569; and Schwarz, et al. (1994) J. Immunother. 16:95-104.
B cell growth and differentiation effects will be analyzed, e.g., by the methodology described, e.g., in Defrance, et al. (1992). J. Exp. Med. 175:671-682; Rousset, et al. (1992) Proc. Nat'l Acad. Sci. USA 89:1890-1893; including IgG2 andIgA2 switch factor assays. Note that, unlike COS7 supernatants, NIH3T3 and COP supernatants apparently do not interfere with human B cell assays.
IX. Generation and Analysis of Genetically Altered Animals
Transgenic mice can be generated by standard methods.
Such animals are useful to determine the effects of deletion of the gene, in specific tissues, or completely throughout the organism. Such may provide interesting insight into development of the animal or particular tissues in various stages. Moreover, the effect on various responses to biological stress can be evaluated. See, e.g., Hogan, et al. (1995) Manipulating the Mouse Embryo: A Laboratory Manual (2d ed.) Cold Spring Harbor Laboratory Press.
A transgenic mouse has been generated, and while the animal seems to survive birth, it fails to thrive, and typically dies within a few weeks. The construct is based upon an actin promoter with a CMV enhancer, which should lead to broad and highexpression. The mice, like IL-6 transgenic mice, are runted. Moreover, they exhibit a bloated abdomen, inflammation of the stomach and intestines, infiltration of cells into the liver, and typically die before day 50. The mice do not breed. A secondsubset of the transgenic mice have a less severe phenotype, and attempts to breed them are taking place.
The genomic structure for the mouse IL-B30 has been determined. A strategy for the production of IL-B30 knockout mice has been developed, and constructs have been started.
All references cited herein are incorporated herein by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference in its entirety for allpurposes.
Many modifications and variations of this invention can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. The specific embodiments described herein are offered by way of example only, and theinvention is to be limited only by the terms of the appended claims, along with the full scope of equivalents to which such claims are entitled.
>
ase pairsnucleic acidsinglelinearcDNACDS at_peptide 64..567 G GGG AGC AGA GCT GTA ATG CTG CTG TTG CTG CTG CCC TGG ACA 48Met Leu Gly Ser Arg Ala Val Met Leu Leu Leu Leu Leu Pro Trp Thr-2CT CAG GGC AGA GCT GTG CCT GGG GGC AGC AGC CCT GCC TGG ACT CAG 96Ala Gln Gly Arg Ala Val Pro Gly Gly Ser Ser ProAla Trp Thr Gln -5 GC CAG CAG CTT TCA CAG AAG CTC TGC ACA CTG GCC TGG AGT GCA CAT Gln Gln Leu Ser Gln Lys Leu Cys Thr Leu Ala Trp Ser Ala His 5CCA CTA GTG GGA CAC ATG GAT CTA AGA GAA GAG GGA GAT GAA GAG ACT Leu Val Gly His MetAsp Leu Arg Glu Glu Gly Asp Glu Glu Thr 3ACA AAT GAT GTT CCC CAT ATC CAG TGT GGA GAT GGC TGT GAC CCC CAA 24n Asp Val Pro His Ile Gln Cys Gly Asp Gly Cys Asp Pro Gln 45 5 CTC AGG GAC AAC AGT CAG TTC TGC TTG CAA AGG ATC CAC CAG GGT288Gly Leu Arg Asp Asn Ser Gln Phe Cys Leu Gln Arg Ile His Gln Gly 6 75CTG ATT TTT TAT GAG AAG CTG CTA GGA TCG GAT ATT TTC ACA GGG GAG 336Leu Ile Phe Tyr Glu Lys Leu Leu Gly Ser Asp Ile Phe Thr Gly Glu 8CCT TCT CTG CTC CCT GAT AGC CCT GTGGCG CAG CTT CAT GCC TCC CTA 384Pro Ser Leu Leu Pro Asp Ser Pro Val Ala Gln Leu His Ala Ser Leu 95 CTG GGC CTC AGC CAA CTC CTG CAG CCT GAG GGT CAC CAC TGG GAG ACT 432Leu Gly Leu Ser Gln Leu Leu Gln Pro Glu Gly His His Trp Glu Thr CAGATT CCA AGC CTC AGT CCC AGC CAG CCA TGG CAG CGT CTC CTT 48n Ile Pro Ser Leu Ser Pro Ser Gln Pro Trp Gln Arg Leu Leu CGC TTC AAA ATC CTT CGC AGC CTC CAG GCC TTT GTG GCT GTA GCC 528Leu Arg Phe Lys Ile Leu Arg Ser Leu Gln Ala Phe ValAla Val Ala GCC CGG GTC TTT GCC CAT GGA GCA GCA ACC CTG AGT CCC TAA 57g Val Phe Ala His Gly Ala Ala Thr Leu Ser Pro no acidsamino acidlinearprotein 2Met Leu Gly Ser Arg Ala Val Met Leu Leu Leu Leu Leu Pro Trp Thr-2la Gln Gly Arg Ala Val Pro Gly Gly Ser Ser Pro Ala Trp Thr Gln -5 ys Gln Gln Leu Ser Gln Lys Leu Cys Thr Leu Ala Trp Ser Ala His 5Pro Leu Val Gly His Met Asp Leu Arg Glu Glu Gly Asp Glu Glu Thr 3Thr Asn Asp Val Pro His IleGln Cys Gly Asp Gly Cys Asp Pro Gln 45 5 Leu Arg Asp Asn Ser Gln Phe Cys Leu Gln Arg Ile His Gln Gly 6 75Leu Ile Phe Tyr Glu Lys Leu Leu Gly Ser Asp Ile Phe Thr Gly Glu 8Pro Ser Leu Leu Pro Asp Ser Pro Val Ala Gln Leu His Ala Ser Leu95 Leu Gly Leu Ser Gln Leu Leu Gln Pro Glu Gly His His Trp Glu Thr Gln Ile Pro Ser Leu Ser Pro Ser Gln Pro Trp Gln Arg Leu Leu Arg Phe Lys Ile Leu Arg Ser Leu Gln Ala Phe Val Ala Val Ala Ala Arg Val PheAla His Gly Ala Ala Thr Leu Ser Pro se pairsnucleic acidsinglelinearcDNACDS ptide TAGAAG TCGGACTACA GAGTTAGACT CAGAACCAAA GGAGGTGGAT AGGGGGTCCA 6TGGT GCAGATCACA GAGCCAGCCA GATCTGAGAA GCAGGGAACA AG ATG -2T TGC AGA GCA GTA ATA ATG CTA TGG CTG TTG CCC TGG GTC ACT Asp Cys Arg Ala Val Ile Met Leu Trp Leu Leu Pro Trp Val Thr-2G GGC CTG GCT GTG CCT AGG AGT AGC AGT CCT GAC TGG GCT CAG TGC 2ly Leu Ala Val Pro Arg Ser SerSer Pro Asp Trp Ala Gln Cys AG CAG CTC TCT CGG AAT CTC TGC ATG CTA GCC TGG AAC GCA CAT GCA 259Gln Gln Leu Ser Arg Asn Leu Cys Met Leu Ala Trp Asn Ala His Ala 5CCA GCG GGA CAT ATG AAT CTA CTA AGA GAA GAA GAG GAT GAA GAG ACT 3la GlyHis Met Asn Leu Leu Arg Glu Glu Glu Asp Glu Glu Thr 3AAA AAT AAT GTG CCC CGT ATC CAG TGT GAA GAT GGT TGT GAC CCA CAA 355Lys Asn Asn Val Pro Arg Ile Gln Cys Glu Asp Gly Cys Asp Pro Gln 45 5GGA CTC AAG GAC AAC AGC CAG TTC TGC TTG CAA AGG ATCCGC CAA GGT 4eu Lys Asp Asn Ser Gln Phe Cys Leu Gln Arg Ile Arg Gln Gly 65 7 GCT TTT TAT AAG CAC CTG CTT GAC TCT GAC ATC TTC AAA GGG GAG 45a Phe Tyr Lys His Leu Leu Asp Ser Asp Ile Phe Lys Gly Glu 8CCT GCT CTA CTC CCT GAT AGCCCC ATG GAG CAA CTT CAC ACC TCC CTA 499Pro Ala Leu Leu Pro Asp Ser Pro Met Glu Gln Leu His Thr Ser Leu 95 CTA GGA CTC AGC CAA CTC CTC CAG CCA GAG GAT CAC CCC CGG GAG ACC 547Leu Gly Leu Ser Gln Leu Leu Gln Pro Glu Asp His Pro Arg Glu Thr CAG ATG CCC AGC CTG AGT TCT AGT CAG CAG TGG CAG CGC CCC CTT 595Gln Gln Met Pro Ser Leu Ser Ser Ser Gln Gln Trp Gln Arg Pro Leu CTC CGT TCC AAG ATC CTT CGA AGC CTC CAG GCC TTT TTG GCC ATA GCT 643Leu Arg Ser Lys Ile Leu Arg Ser Leu GlnAla Phe Leu Ala Ile Ala CGG GTC TTT GCC CAC GGA GCA GCA ACT CTG ACT GAG CCC TTA GTG 69g Val Phe Ala His Gly Ala Ala Thr Leu Thr Glu Pro Leu Val ACA GCT TAAGGATGCC CAGGTTCCCA TGGCTACCAT GATAAGACTA 74r AlaATCAGC CCAGACATCT ACCAGTTAAT TAACCCATTA GGACTTGTGC TGTTCTTGTT 8TGTTT TGCGTGAAGG GCAAGGACAC CATTATTAAA GAGAAAAGAA ACAAACCCCA 86GCAG CTGGCTAGAG AAAGGAGCTG GAGAAGAAGA ATAAAGTCTC GAGCCCTTGG 92AAGC GGGCAAGCAG CTGCGTGGCC TGAGGGGAAGGGGGCGGTGG CATCGAGAAC 98GAAA ACCCAGAGCA TCAGAAAAAG TGAGCCCAGG CTTTGGCCAT TATCTGTAAG AACAAGA AAAGGGGAAC ATTATACTTT CCTGGGTGGC TCAGGGAAAT GTGCAGATGC GTACTCC AGACAGCAGC TCTGTACCTG CCTGCTCTGT CCCTCAGTTC TAACAGAATC TCACTAAGAACTAACAG GACTACCAAT ACGAACTGAC AAA amino acidsamino acidlinearprotein 4Met Leu Asp Cys Arg Ala Val Ile Met Leu Trp Leu Leu Pro Trp Val-2hr Gln Gly Leu Ala Val Pro Arg Ser Ser Ser Pro Asp Trp Ala Gln -5 ys Gln Gln Leu SerArg Asn Leu Cys Met Leu Ala Trp Asn Ala His 5Ala Pro Ala Gly His Met Asn Leu Leu Arg Glu Glu Glu Asp Glu Glu 3Thr Lys Asn Asn Val Pro Arg Ile Gln Cys Glu Asp Gly Cys Asp Pro 45 5 Gly Leu Lys Asp Asn Ser Gln Phe Cys Leu Gln Arg IleArg Gln 6 75Gly Leu Ala Phe Tyr Lys His Leu Leu Asp Ser Asp Ile Phe Lys Gly 8Glu Pro Ala Leu Leu Pro Asp Ser Pro Met Glu Gln Leu His Thr Ser 95 Leu Leu Gly Leu Ser Gln Leu Leu Gln Pro Glu Asp His Pro Arg Glu Gln GlnMet Pro Ser Leu Ser Ser Ser Gln Gln Trp Gln Arg Pro Leu Arg Ser Lys Ile Leu Arg Ser Leu Gln Ala Phe Leu Ala Ile Ala Ala Arg Val Phe Ala His Gly Ala Ala Thr Leu Thr Glu Pro Leu Pro Thr Ala aminoacidsamino acidNot Relevantlinearpeptide 5Ser Cys Leu Gln Arg Ile His Gln Gly Leu Val Phe Tyr Glu Lys Leuly Ser Asp Ile Phe Thr Gly Glu Pro Ser Leu His Pro Asp Gly 2Ser Val Gly Gln Leu His Ala Ser Leu Leu Gly Leu Arg Gln Leu Leu 354 Pro Glu Gly His His Trp Glu Thr Glu Gln Thr Pro Ser Pro Ser 5Pro Ser Gln Pro Trp Gln Arg Leu Leu Leu Arg Leu Lys Ile Leu Arg65 7Ser Leu Gln Ala Phe Val Ala Val Ala Ala Arg Val Phe Ala His Gly 85 9 Ala Thr Leu Ser Gln amino acidsamino acidNot Relevantlinearpeptide 6Thr Pro Leu Gly Pro Ala Arg Ser Leu Pro Gln Ser Phe Leu Leu Lyseu Glu Gln Val Arg Lys Ile Gln Ala Asp Gly Ala Glu Leu Gln 2Glu Arg Leu Cys Ala Ala His Lys Leu Cys His Pro Glu Glu LeuMet 35 4 Leu Arg His Ser Leu Gly Ile Pro Gln Ala Pro Leu Ser Ser Cys 5Ser Ser Gln Ser Leu Gln Leu Arg Gly Cys Leu Asn Gln Leu His Gly65 7Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Ala Gly Ile Ser 85 9 Glu Leu Ala Pro ThrLeu Asp Thr Leu Gln Leu Asp Val Thr Asp Ala Thr Asn Ile Trp Leu Gln Met Glu Asp Leu Gly Ala Ala Pro Val Gln Pro Thr Gln Gly Ala Met Pro Thr Phe Thr Ser Ala Phe Arg Arg Ala Gly Gly Val Leu Val Ala Ser Gln LeuHis Arg Phe Leu Glu Leu Ala Tyr Arg Gly Leu Arg Tyr Leu Ala Glu Pro no acidsamino acidNot Relevantlinearpeptide 7Thr Pro Leu Gly Pro Thr Ser Ser Leu Pro Gln Ser Phe Leu Leu Lyseu Glu Gln Val Arg Lys Val Gln AlaAsp Gly Thr Ala Leu Gln 2Glu Arg Leu Cys Ala Ala His Lys Leu Cys His Pro Glu Glu Leu Val 35 4 Leu Gly His Ala Leu Gly Ile Pro Gln Ala Pro Leu Ser Ser Cys 5Ser Ser Gln Ala Leu Gln Leu Thr Gly Cys Leu Arg Gln Leu His Ser65 7GlyLeu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Ala Gly Ile Ser 85 9 Glu Leu Ala Pro Thr Leu Asp Met Leu Gln Leu Asp Ile Thr Asp Ala Ile Asn Ile Trp Gln Gln Met Glu Asp Val Gly Met Ala Pro Val Pro Pro Thr Gln Gly Thr MetPro Thr Phe Thr Ser Ala Phe Arg Arg Ala Gly Gly Thr Leu Val Ala Ser Asn Leu Gln Ser Phe Leu Glu Val Ala Tyr Arg Ala Leu Arg His Phe Thr Lys Pro no acidsamino acidNot Relevantlinearpeptide 8Thr Pro Leu Gly ProAla Ser Ser Leu Pro Gln Ser Phe Leu Leu Lyseu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln 2Glu Lys Leu Val Ser Glu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu 35 4 Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp AlaPro Leu 5Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Glu65 7Leu His Ser Gly Leu Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala 85 9 Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Ala Ser HisLeu Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu His Leu Ala Gln Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile Trp GlnGln Met Glu Glu Leu Gly 78 amino acidsamino acidNot Relevantlinearpeptide 9Val Pro Leu Val Thr Val Ser Ala Leu Pro Pro Ser Leu Pro Leu Proer Phe Leu Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Ala 2Ser Gly Ser Val LeuLeu Glu Gln Leu Cys Ala Thr Tyr Lys Leu Cys 35 4 Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Lys 5Ala Ser Leu Ser Gly Cys Ser Ser Gln Ala Leu Gln Gln Thr Gln Cys65 7Leu Ser Gln Leu His Ser Gly Leu Cys Leu Tyr Gln Gly LeuLeu Gln 85 9 Leu Ser Gly Ile Ser Pro Ala Leu Ala Pro Thr Leu Asp Leu Leu Leu Asp Val Ala Asn Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Leu Gly Val Ala Pro Thr Val Gln Pro Thr Gln Ser Ala Met Pro Phe ThrSer Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Ala Ile Ser Tyr Leu Gln Gly Phe Leu Glu Thr Ala Arg Leu Ala Leu His His Alano acidsamino acidNot Relevantlinearpeptide he Pro Thr Pro Gly Pro Leu Gly Gly Asp Ser LysAsp Asp Alaer Asn Arg Pro Pro Leu Thr Ser Ala Asp Lys Met Glu Asp Phe 2Ile Lys Phe Ile Leu Gly Lys Ile Ser Ala Leu Arg Asn Glu Met Cys 35 4 Lys Tyr Asn Lys Cys Glu Asp Ser Lys Glu Val Leu Ala Glu Asn 5Asn Leu Asn LeuPro Lys Leu Ala Glu Lys Asp Arg Cys Phe Gln Ser65 7Arg Phe Asn Gln Glu Thr Cys Leu Thr Arg Ile Thr Thr Gly Leu Gln 85 9 Phe Gln Ile His Leu Lys Tyr Leu Glu Ser Asn Tyr Glu Gly Asn Asp Asn Ala His Ser Val Tyr Ile Ser Thr LysHis Leu Leu Gln Leu Arg Pro Met Asn Gln Ile Glu Val Thr Thr Pro Asp Pro Thr Asp Ala Ser Leu Gln Ala Leu Phe Lys Ser Gln Asp Lys Trp Leu Lys His Thr Thr Ile His Leu Ile Leu Arg Arg Leu Glu Asp Phe Leu Phe Ser Leu Arg Ala Ile Arg Ile Met no acidsamino acidNot Relevantlinearpeptide he Pro Thr Pro Gly Pro Leu Gly Gly Asp Ala Thr Ser Asn Argro Leu Thr Pro Ala Asp Lys Met Glu Glu Leu Ile Lys Tyr Ile 2Leu GlyLys Ile Ser Ala Leu Lys Lys Glu Met Cys Asp Asn Tyr Asn 35 4 Cys Glu Asp Ser Lys Glu Ala Leu Ala Glu Asn Asn Leu Asn Leu 5Pro Lys Leu Ala Glu Lys Asp Gly Cys Phe Gln Ser Gly Phe Asn Gln65 7Glu Thr Cys Leu Thr Arg Ile Thr Thr Gly LeuGln Glu Phe Gln Ile 85 9 Leu Lys Phe Leu Gln Asp Lys Tyr Glu Gly Asp Lys Glu Asn Ala Ser Val Tyr Thr Ser Thr Asn Val Leu Leu Gln Met Leu Lys Arg Gly Lys Asn Gln Asp Glu Val Thr Ile Pro Val Pro Thr Val Glu Gly Leu Gln Leu Ser Cys Ser His Arg Arg Val Ala Glu Ala His Asn Asn His Leu Thr Leu Arg Arg Leu Glu Asp Phe Leu Gln Leu Arg Arg Ala Val Arg Ile Met amino acidsamino acidsinglelinearpeptide he Pro Ala ProVal Pro Pro Gly Glu Asp Ser Lys Asp Val Alaro His Arg Gln Pro Leu Thr Ser Ser Glu Arg Ile Asp Lys Gln 2Ile Arg Tyr Ile Leu Asp Gly Ile Ser Ala Leu Arg Lys Glu Thr Cys 35 4 Lys Ser Asn Met Cys Glu Ser Ser Lys Glu Ala Leu AlaGlu Asn 5Asn Leu Asn Leu Pro Lys Met Ala Glu Lys Asp Gly Cys Phe Gln Ser65 7Gly Phe Asn Glu Glu Thr Cys Leu Val Lys Ile Ile Thr Gly Leu Leu 85
9 Phe Glu Val Tyr Leu Glu Tyr Leu Gln Asn Arg Phe Glu Ser Ser Glu Gln Ala Arg Ala Val Gln Met Ser Thr Lys Val Leu Ile Gln Leu Gln Lys Lys Ala Lys Asn Leu Asp Ala Ile Thr Thr Pro Asp Thr Thr AsnAla Ser Leu Leu Thr Lys Leu Gln Ala Gln Asn Gln Trp Leu Gln Asp Met Thr Thr His Leu Ile Leu Arg Ser Phe Lys Glu Leu Gln Ser Ser Leu Arg Ala Leu Arg Gln Met no acidsamino acidNot Relevantlinearpeptide hePro Thr Pro Gly Pro Leu Gly Glu Asp Phe Lys Asn Asp Thrro Ser Arg Leu Leu Leu Thr Thr Pro Glu Lys Thr Glu Ala Leu 2Ile Lys His Ile Val Asp Lys Ile Ser Ala Ile Arg Lys Glu Ile Cys 35 4 Lys Asn Asp Glu Cys Glu Asn Ser Lys GluThr Leu Ala Glu Asn 5Lys Leu Lys Leu Pro Lys Met Glu Glu Lys Asp Gly Cys Phe Gln Ser65 7Gly Phe Asn Gln Ala Ile Cys Leu Ile Lys Thr Thr Ala Gly Leu Leu 85 9 Tyr Gln Ile Tyr Leu Asp Phe Leu Gln Asn Glu Phe Glu Gly Asn Glu Thr Val Met Glu Leu Gln Ser Ser Ile Arg Thr Leu Ile Gln Leu Lys Glu Lys Ile Ala Gly Leu Ile Thr Thr Pro Ala Thr His Asp Met Leu Glu Lys Met Gln Ser Ser Asn Glu Trp Val Lys Asn Ala Lys Val Ile Ile Ile LeuArg Ser Leu Glu Asn Phe Leu Gln Phe Leu Arg Ala Ile Arg Met Lys amino acidsamino acidNot Relevantlinearpeptide he Pro Thr Ser Gln Val Arg Arg Gly Asp Phe Thr Glu Asp Thrro Asn Arg Pro Val Tyr Thr Thr Ser Gln ValGly Gly Leu Ile 2Thr His Val Leu Trp Glu Ile Val Glu Met Arg Lys Glu Leu Cys Asn 35 4 Asn Ser Asp Cys Met Asn Asn Asp Asp Ala Leu Ala Glu Asn Asn 5Leu Lys Leu Pro Glu Ile Gln Arg Asn Asp Gly Cys Tyr Gln Thr Gly65 7Tyr Asn GlnGlu Ile Cys Leu Leu Lys Ile Ser Ser Gly Leu Leu Glu 85 9 His Ser Tyr Leu Glu Tyr Met Lys Asn Asn Leu Lys Asp Asn Lys Asp Lys Ala Arg Val Leu Gln Arg Asp Thr Glu Thr Leu Ile His Phe Asn Gln Glu Val Lys Asp Leu His LysIle Val Leu Pro Thr Ile Ser Asn Ala Leu Leu Thr Asp Lys Leu Glu Ser Gln Lys Glu Trp Leu Arg Thr Lys Thr Ile Gln Phe Ile Leu Lys Ser Leu Glu Glu Leu Lys Val Thr Leu Arg Ser Thr Arg Gln Thr noacidsamino acidNot Relevantlinearpeptide ro Leu Ala Glu Leu Ser Gly Asp His Asp Phe Gln Leu Phe Leuys Asn Leu Glu Phe Thr Arg Lys Ile Arg Gly Asp Val Ala Ala 2Leu Gln Arg Ala Val Cys Asp Thr Phe Gln Leu Cys Thr Glu Glu Glu 354 Gln Leu Val Gln Pro Asp Pro His Leu Val Gln Ala Pro Leu Asp 5Gln Cys His Lys Arg Gly Phe Gln Ala Glu Val Cys Phe Thr Gln Ile65 7Arg Ala Gly Leu His Ala Tyr His Asp Ser Leu Gly Ala Val Leu Arg 85 9 Leu Pro Asn His Thr Thr LeuVal Glu Thr Leu Gln Leu Asp Ala Asn Leu Ser Ser Asn Ile Gln Gln Gln Met Glu Asp Leu Gly Leu Thr Val Thr Leu Pro Ala Glu Gln Arg Ser Pro Pro Pro Thr Phe Gly Pro Phe Gln Gln Gln Val Gly Gly Phe Phe Ile Leu AlaAsn Phe Gln Arg Phe Leu Glu Thr Ala Tyr Arg Ala Leu Arg His Leu Ala Leuno acidsamino acidNot Relevantlinearpeptide rg Gly Lys Leu Pro Asp Ala Pro Glu Phe Glu Lys Asp Leu Leuln Arg Leu Asn Trp MetLeu Trp Val Ile Asp Glu Cys Phe Arg 2Asp Leu Cys Tyr Arg Thr Gly Ile Cys Lys Gly Ile Leu Glu Pro Ala 35 4 Ile Phe His Leu Lys Leu Pro Ala Ile Asn Asp Thr Asp His Cys 5Gly Leu Ile Gly Phe Asn Glu Thr Ser Cys Leu Lys Lys Leu Ala Asp657Gly Phe Phe Glu Phe Glu Val Leu Phe Lys Phe Leu Thr Thr Glu Phe 85 9 Lys Ser Val Ile Asn Val Asp Val Met Glu Leu Leu Thr Lys Thr Gly Trp Asp Ile Gln Glu Glu Leu Asn Lys Leu Thr Lys Thr His Ser Pro Pro Lys PheAsp Arg Gly Leu Leu Gly Arg Leu Gln Gly Lys Tyr Trp Val Arg His Phe Ala Ser Phe Tyr Val Leu Ser Ala Met Glu Lys Phe Ala Gly Gln Ala Val Arg Val Leu Asp Ser Ile Pro Val Thr Pro Asp Val His Asp Lys
* * * * * |
|
|
|
